biotech Value proposition
AI for digital twin of cells
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.
While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.
The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
Drug Discovery, Pharmaceutical, Deep Learning, and BiotechOriginal language
AI for digital twin of cells
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.
While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.
The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
DeepLife | Digital Twin of Cells for Drug Discovery
At DeepLife, we harness deep learning on multi-omics data to model cells and efficiently engineer their behavior
https://www.deeplife.co/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 21 Jun 2024 | | |
 Orange Telecoms, Law Practice, Telecommunications | Orange Telecoms, Law Practice, Telecommunications | Other 25 May 2024 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 23 Aug 2023 | | |
 France Digitale Startup accelerator & VC, Non-profit Organizations | France Digitale Startup accelerator & VC, Non-profit Organizations | Other 31 Oct 2021 | | |
 Avolta Finance, Investment Banking | Avolta Finance, Investment Banking | Other 2 Oct 2022 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 8 Jul 2020 | | |
 Digital Pharma Lab Pharmaceutical, Health, Business Consulting and Services | Digital Pharma Lab Pharmaceutical, Health, Business Consulting and Services | Not capitalistic Partnership Not event 22 Jun 2020 | | |